Literature DB >> 35044790

Loss of TDP-43 function and rimmed vacuoles persist after T cell depletion in a xenograft model of sporadic inclusion body myositis.

Kyla A Britson1, Jonathan P Ling2, Kerstin E Braunstein2, Janelle M Montagne2, Jenna M Kastenschmidt3, Andrew Wilson1, Chiseko Ikenaga1, William Tsao1, Iago Pinal-Fernandez1,4, Katelyn A Russell1, Nicole Reed1, Tahseen Mozaffar5, Kathryn R Wagner1,6, Lyle W Ostrow1, Andrea M Corse1, Andrew L Mammen1,4, S Armando Villalta3, H Benjamin Larman2, Philip C Wong2,7, Thomas E Lloyd1,7.   

Abstract

Sporadic inclusion body myositis (IBM) is the most common acquired muscle disease in adults over age 50, yet it remains unclear whether the disease is primarily driven by T cell–mediated autoimmunity. IBM muscle biopsies display nuclear clearance and cytoplasmic aggregation of TDP-43 in muscle cells, a pathologic finding observed initially in neurodegenerative diseases, where nuclear loss of TDP-43 in neurons causes aberrant RNA splicing. Here, we show that loss of TDP-43–mediated splicing repression, as determined by inclusion of cryptic exons, occurs in skeletal muscle of subjects with IBM. Of 119 muscle biopsies tested, RT-PCR–mediated detection of cryptic exon inclusion was able to diagnose IBM with 84% sensitivity and 99% specificity. To determine the role of T cells in pathogenesis, we generated a xenograft model by transplanting human IBM muscle into the hindlimb of immunodeficient mice. Xenografts from subjects with IBM displayed robust regeneration of human myofibers and recapitulated both inflammatory and degenerative features of the disease. Myofibers in IBM xenografts showed invasion by human, oligoclonal CD8+ T cells and exhibited MHC-I up-regulation, rimmed vacuoles, mitochondrial pathology, p62-positive inclusions, and nuclear clearance and cytoplasmic aggregation of TDP-43, associated with cryptic exon inclusion. Reduction of human T cells within IBM xenografts by treating mice intraperitoneally with anti-CD3 (OKT3) suppressed MHC-I up-regulation. However, rimmed vacuoles and loss of TDP-43 function persisted. These data suggest that T cell depletion does not alter muscle degenerative pathology in IBM.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35044790      PMCID: PMC9118725          DOI: 10.1126/scitranslmed.abi9196

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   19.319


  30 in total

1.  TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD.

Authors:  Jonathan P Ling; Olga Pletnikova; Juan C Troncoso; Philip C Wong
Journal:  Science       Date:  2015-08-07       Impact factor: 47.728

2.  Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle.

Authors:  Michael C Sugarman; Tritia R Yamasaki; Salvatore Oddo; Julio C Echegoyen; M Paul Murphy; Todd E Golde; Mehrdad Jannatipour; Malcolm A Leissring; Frank M LaFerla
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

3.  Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43.

Authors:  Magdalini Polymenidou; Clotilde Lagier-Tourenne; Kasey R Hutt; Stephanie C Huelga; Jacqueline Moran; Tiffany Y Liang; Shuo-Chien Ling; Eveline Sun; Edward Wancewicz; Curt Mazur; Holly Kordasiewicz; Yalda Sedaghat; John Paul Donohue; Lily Shiue; C Frank Bennett; Gene W Yeo; Don W Cleveland
Journal:  Nat Neurosci       Date:  2011-02-27       Impact factor: 24.884

4.  Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis.

Authors:  H Benjamin Larman; Mohammad Salajegheh; Remedios Nazareno; Theresa Lam; John Sauld; Hanno Steen; Sek Won Kong; Jack L Pinkus; Anthony A Amato; Stephen J Elledge; Steven A Greenberg
Journal:  Ann Neurol       Date:  2013-03       Impact factor: 10.422

5.  PTBP1 and PTBP2 Repress Nonconserved Cryptic Exons.

Authors:  Jonathan P Ling; Resham Chhabra; Jonathan D Merran; Paul M Schaughency; Sarah J Wheelan; Jeffry L Corden; Philip C Wong
Journal:  Cell Rep       Date:  2016-09-27       Impact factor: 9.423

Review 6.  Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.

Authors:  B Rubio-Viqueira; M Hidalgo
Journal:  Clin Pharmacol Ther       Date:  2008-11-12       Impact factor: 6.875

7.  Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis.

Authors:  O Dubourg; J Wanschitz; T Maisonobe; A Béhin; Y Allenbach; S Herson; O Benveniste
Journal:  Acta Myol       Date:  2011-10

8.  Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies.

Authors:  Annie Hiniker; Brianne H Daniels; Han S Lee; Marta Margeta
Journal:  Acta Neuropathol Commun       Date:  2013-07-01       Impact factor: 7.801

Review 9.  Immune and myodegenerative pathomechanisms in inclusion body myositis.

Authors:  Christian W Keller; Jens Schmidt; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2017-05-16       Impact factor: 4.511

10.  ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair.

Authors:  Joseph R Klim; Luis A Williams; Francesco Limone; Irune Guerra San Juan; Brandi N Davis-Dusenbery; Daniel A Mordes; Aaron Burberry; Michael J Steinbaugh; Kanchana K Gamage; Rory Kirchner; Rob Moccia; Seth H Cassel; Kuchuan Chen; Brian J Wainger; Clifford J Woolf; Kevin Eggan
Journal:  Nat Neurosci       Date:  2019-01-14       Impact factor: 24.884

View more
  4 in total

Review 1.  Inclusion body myositis: evolving concepts.

Authors:  Mari Perez-Rosendahl; Tahseen Mozaffar
Journal:  Curr Opin Neurol       Date:  2022-10-01       Impact factor: 6.283

Review 2.  Inclusion body myositis and associated diseases: an argument for shared immune pathologies.

Authors:  Christopher Nelke; Felix Kleefeld; Corinna Preusse; Tobias Ruck; Werner Stenzel
Journal:  Acta Neuropathol Commun       Date:  2022-06-03       Impact factor: 7.578

Review 3.  Expanding the TDP-43 Proteinopathy Pathway From Neurons to Muscle: Physiological and Pathophysiological Functions.

Authors:  Lauren Versluys; Pedro Ervilha Pereira; Nika Schuermans; Boel De Paepe; Jan L De Bleecker; Elke Bogaert; Bart Dermaut
Journal:  Front Neurosci       Date:  2022-02-03       Impact factor: 4.677

Review 4.  Inclusion body myositis: Update on the diagnostic and therapeutic landscape.

Authors:  Elie Naddaf
Journal:  Front Neurol       Date:  2022-09-27       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.